Pharmacopeia gets Bristol exec
Executive Summary
Rene Belder, who led Bristol-Myers Squibb's regulatory team for the PPAR agonist Pargluva (muraglitazar), joins Pharmacopeia as VP-clinical and regulatory affairs, the Princeton, N.J. biotech announces Nov. 6. Bristol halted development of Pargluva in May, seven months after an FDA "approvable" letter for the diabetes agent suggested additional clinical trials would be necessary (1"The Pink Sheet" Dec. 19, 2005, p. 11). At Pharmacopeia, Belder will be responsible for overseeing the firm's current and future clinical development product portfolio...
You may also be interested in...
Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink
Bristol-Myers Squibb will undertake a cost-cutting program to offset the impact of the development delay of the investigational type 2 diabetes drug Pargluva.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.